Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma

The Health Technology Assessment (HTA) evaluates the efficacy, safety, cost effectiveness and budgetary impact of monthly treatment with bone-targeted agents compared with trimonthly treatment of patients with bone metastases from solid tumours and multiple myeloma.
The scoping report determines the feasibility of conducting an HTA.

Last modification 07.06.2021

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Berne
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/bonetargetingagents.html